ClinicalTrials.gg
CompletedNCT01416441Updated Oct 7, 2021Results posted

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

A Phase 3 interventional study of Aripiprazole in Tourette's Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 80 sites in 10 countries. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-10-07.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Not applicable
Ages
7 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing aripiprazole in Tourette Syndrome — none open to participants now, none under way, none of them phase 3. Aripiprazole · Tourette Syndrome.

Enrollment
Largest of 10
170 · median 97
Started
2011
with 2 others
Phase 3
7 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
6 of 10
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 10 studies testing aripiprazole in Tourette Syndrome, this one has the largest enrollment, is one of 3 that started in 2011, is one of 7 in phase 3, and was the 4th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

None of the 10 studies testing aripiprazole in Tourette Syndrome is open now. The open studies under Tourette Syndrome, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 7 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing aripiprazole in Tourette Syndrome as a file.
02

Study summary

The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.

03

Conditions studied

  • Tourette's Disorder

Keywords

  • Tourette's Disorder
  • Tic Disorders
04

Who can participate

Ages eligible
7 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participants successfully completed the final assessment visit in either Study 31-10-272 (NCT01418339) or 31-10-273 (NCT01418352). The participants completed all required assessments for the Week 8/Early Termination Visit to be eligible for rollover in to this open-label trial.
  • Written form (ICF) obtained from a legally acceptable representative \& informed assent at Baseline as applicable by trial center's Institutional review board/independent ethics committee (IRB/IEC).
  • The participant, designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator.

Exclusion criteria

Exclusion Criteria:

  • The participants experienced adverse events (AEs) during the double-blind study 31-10-272 (NCT01418339) or 31-10-273 (NCT01418352) that would, in the investigator's judgment, preclude further exposure to aripiprazole.
  • The participants had protocol violations during the double-blind trial considered major in the judgment of the investigator which would deem the participant a poor candidate for the trial.
  • A positive drug screen at baseline for cocaine, alcohol or other drugs of abuse which will result in early termination at Week 1.
  • Sexually active patients who will not commit to utilizing 2 of the approved methods or who will not remain abstinent during the trial and for 90 and 30 days following the last dose of study drug for male and female respectively.
  • Participants representing Risk of committing suicide.
  • Body weight lower than 16 kg.
  • Abnormal laboratory test results (, , Neutrophils, , Alanine aminotransferase, Creatinine) vital signs and (ECG) results.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Aripiprazole

    Participants received oral aripiprazole tablets once weekly (QW) with a titrated dose starting from 52.5 milligram (mg), on Day 1 and increasing to 77.5 mg and 110 mg for the remainder of the trial (Up to Week 52), the dose could be adjusted between these 3 dose levels as determined by investigator's discretion based on safety and tolerability.

    Drug: Aripiprazole

Interventions

  • Aripiprazole tablets orally once daily.

    Also known as: ABILIFY

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs and TEAEs Leading Treatment Discontinuation

    An Adverse Event (AE) is defined as any untoward medical occurrence in a participant enrolled in a clinical trial and which did not necessarily have a causal relationship with the study medication. Treatment emergent adverse events (TEAE) are adverse events occurring after the onset of study drug administration.

    Time frame: From signing of the informed consent up to 30 days after the last dose (Up to Week 52)

  2. Number of Participants With Clinically Significant Changes in Laboratory Parameter Values

    The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Participants with potentially clinically significant lab values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria were reported. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance.

    Time frame: Baseline to Week 52

  3. Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values

    Incidence of clinically relevant abnormal ECG values were reported as change from Baseline in heart rate (Tachycardia - ≥15 beats per minute (bpm), Bradycardia ≤15 bpm; Rhythm (Sinus tachycardia ≥15 bpm increase, Sinus bradycardia decrease of ≥15 bpm from Baseline); Presence of - supraventricular premature beat; ventricular premature beat; supraventricular tachycardia; ventricular tachycardia; atrial fibrillation and flutter. Conduction - Presence of primary, secondary or tertiary atrioventricular block, left bundle-branch block, right bundle-branch block, pre-excitation syndrome, other intraventricular conduction blocked QRS ≥0.12 second increase of ≥0.02 second. Acute, subacute or old Infarction, Presence of myocardial ischemia, symmetrical T-wave inversion. Increase in QTc - QTc ≥450 msec ≥10% increase. Any clinically significant change from Baseline assessed by the Investigator are reported.

    Time frame: Baseline to Week 52

  4. Number of Participants With Emergence of Suicidal Ideation, TEAEs Related to Suicide and Suicidality and Suicide Ideation From the Potential Suicide Events Recorded on the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale.

    Time frame: Baseline to Week 52

  5. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score

    The AIMS Scale is an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10) are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

  6. Mean Change From Baseline in Body Mass Index (BMI)

    The BMI kilogram/meter square (i.e. kg/m\^2) was calculated from the Baseline height and the weight at the current visit using one of the following formulae, as appropriate: Weight (kg) divided by \[Height (meters)\]\^2.

    Time frame: Baseline and Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)

  7. Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs assessments included orthostatic (supine and standing) blood pressure (BP) measured as millimeter of mercury \[mmHg\]), heart rate, (measured in beats per minute \[bpm\]), body weight (measured in kilograms \[kg\]) and body temperature. Incidence of clinically relevant abnormal values in heart rate, systolic and diastolic blood pressure and weight were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant has been supine for at least 5 minutes and again after the participant has been standing for approximately 2 minutes, but not more than 3 minutes.

    Time frame: Baseline to Week 52

  8. Mean Change From Baseline in Simpson Angus Scale (SAS) Score

    The SAS is a rating scale used to measure Extrapyramidal symptoms (EPS). The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

  9. Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score

    The BARS was an EPS rating scale. The BARS was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia). A negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

  10. Mean Change From Baseline in Average Score of Attention-Deficit Disorder/Attention-Deficit Hyperactivity Disorder (ADD/ADHD) Sub-scale of the Swanson, Nolan and Pelham-IV (SNAP-IV)

    The SNAP-IV, ADHD Inattention subscale contains 19 items, items 1 to 9 measure inattention, items 11 to 19 measure hyperactivity/impulsivity, and item 10 for inattention domain that scores the intensity of each item during the last seven days on a 0 to 3 scale (0=not at all, 1=just a little, 2=pretty much, 3=very much). The lowest possible score is 0; highest is 57. The negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

  11. Mean Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Total Score

    The CY-BOCS is used to assess characteristics of obsession and compulsion for the week prior to the interview. Nineteen items are rated in the CY-BOCS, but the total score is the sum of only items 1 to 10 (excluding items 1b and 6b). The obsession and compulsion subtotals are the sums of items 1 to 5 (excluding 1b) and 6 to 10 (excluding 6b), respectively. A missing value for any CY-BOCS item scale could result in a missing total score or obsession and compulsion subtotals of which the item scale is a component. At baseline, the full CY-BOCS interview is conducted. At all post-baseline time points, the "Questions on Obsessions" (items 1 to 5) and "Questions on Compulsions" (items 6 to 10) are reviewed and the target symptoms identified at baseline are the primary focus for rating severity. CY-BOCS total score could range from 0 to 40. Higher scores indicate worse outcome. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

  12. Mean Change From Baseline in Children's Depression Rating Scale Revised (CDRS-R) Total Score

    The CDRS-R is composed of 17 interviewer-rated symptom areas: impaired schoolwork, difficulty having fun, social withdrawal, appetite disturbance, sleep disturbance, excessive fatigue, physical complaints, irritability, excessive guilt, low self-esteem, depressed feelings, morbid ideas, suicidal ideas, excessive weeping, depressed facial affect, listless speech, and hypoactivity. The CDRS-R total score is the sum of scores for the 17 symptom areas. A missing value for any CDRS-R item scale or a not rated item scale (indicated by the value of 0) could result in a missing total score. The CDRS-R total score is the sum of scores for the 17 symptom areas and could range from 17 to 113 with higher values indicating worse outcome. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

  13. Mean Change From Baseline in Pediatric Anxiety Rating Scale (PARS) Total Severity Score

    The PARS has 2 sections: the symptom checklist and the severity items. The symptom checklist is used to determine the child's repertoire of symptoms during the past week. Information is elicited from the child and parent(s) and the rater then combines information from all informants using his/her best judgment. The 7-item severity list is used to determine severity of symptoms and the PARS total score. The time frame for the PARS rating is the past week. Only those symptoms endorsed for the past week are included in the symptom checklist and rated on the severity items. The PARS total severity score is the sum of items 2, 3, 5, 6, and 7. The total severity score ranges from 0 to 25, with 25 being the worst. Codes "8" (Not applicable) and "9" (Does not know) are not included in the summation (ie, equivalent to a score of 0 in the summation). A negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

  14. Mean Change From Baseline in Body Weight

    Time frame: Baseline to Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)

  15. Mean Change From Baseline in Waist Circumference

    Waist circumference was recorded before a participant's meal and at approximately the same time at each visit. Measurement was accomplished by locating the upper hip bone and the top of the right iliac crest and placing the measuring tape in a horizontal plane around the abdomen at the level of the crest. Before reading the tape measure, the assessor assured that the tape was snug, but did not compress the skin, and is parallel to the floor. The measurement was made at the end of a normal exhalation.

    Time frame: Baseline to Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)

Secondary outcomes

  1. Mean Change From Baseline in Yale Global Tic Severity Scale (YGTSS) Total Tic Score

    The YGTSS is a semi-structured clinical interview designed to measure the tic severity. This scale consisted of a tic inventory, with 5 separate rating scales to rate the severity of symptoms, and an impairment ranking. Ratings were made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics, each including number, frequency, intensity, complexity, and interference. The YGTSS TTS was the summation of the severity scores of motor and vocal tics. The total tic score (TTS) ranged from 0 (none) to 50 (severe) with higher score represent more severe symptoms (A negative change from Baseline indicates improvement).

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

  2. Mean Change From Baseline in Clinical Global Impression for Tourette's Syndrome (CGI-TS) Severity of Illness Score

    The severity of illness and efficacy of study medication for each participant were rated using the CGI-TS scale. The study physician rated the participants total improvement whether or not it is due to study treatment. All responses were compared to the participants condition at Baseline (Day 0). Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

  3. Mean Change From Baseline in Total YGTSS Score

    The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) of motor and vocal tics, and an impairment ranking. The Total YGTSS score is the summation of the severity scores of motor and vocal tics and also the ranking of impairment (range of 0 to 100). A missing value of a YGTSS item scale could result in a missing Total YGTSS score. A negative change in Total YGTSS score from baseline represents an improvement in symptoms.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

  4. Response Rates

    Response rates - clinical response was defined as percentage of participants \>25% improvement from Baseline to endpoint in YGTSS TTS OR a CGI-TS change score of 1 \[very much improved\] or 2 \[much improved\] at endpoint. The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) of motor and vocal tics, and an impairment ranking. The Total YGTSS score is the summation of the severity scores of motor and vocal tics and also the ranking of impairment (range of 0 to 100) with higher score representing severe symptoms.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

  5. Treatment Discontinuation Rates

    Treatment discontinuation rate was calculated as the percentage of participants who discontinued treatment.

    Time frame: Up to Week 53

  6. Mean Change From Baseline in Gilles de la Tourette Quality of Life (GTS-QOL) Overall Score

    The GTS-QOL is a disease-specific patient-reported scale for the measurement of health-related quality of life in participants with Tourette's Disorder, taking into account the complexity of the clinical picture of the disease. The questionnaire consists of a 27-item Tourette's Disorder-specific scale with 4 subscales (psychological, physical, obsessional, and cognitive). The GTS-QOL total score ranged from 0 (extremely dissatisfied with life) and 100 (extremely satisfied with life). A positive change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 4, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)

07

Results

Posted Oct 7, 2021

Participant flow

A total of 170 participants were screened and enrolled. 114 participants were enrolled from study 31-10-272 (NCT01418339) and 56 participants were enrolled from study 31-10-273 (NCT01418352). The participants were recruited at 79 sites in following 10 countries: Bulgaria, Canada, Germany, Hungary, Mexico, Romania, South Korea, Taiwan, Ukraine and the US from 19 October 2011 to 13 March 2014.

Participant flow — Overall Study
MilestoneAripiprazole (Once Weekly)
Started170
Completed89
Not completed81
Withdrew: Lost to follow-up5
Withdrew: Adverse event6
Withdrew: Sponsor discontinued trial site43
Withdrew: Subject met withdrawal criteria10
Withdrew: Investigator withdrew subject2
Withdrew: Subject withdrew consent12
Withdrew: Lack of efficacy as determined by the investigator3

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs and TEAEs Leading Treatment Discontinuation

An Adverse Event (AE) is defined as any untoward medical occurrence in a participant enrolled in a clinical trial and which did not necessarily have a causal relationship with the study medication. Treatment emergent adverse events (TEAE) are adverse events occurring after the onset of study drug administration.

Time frame:
From signing of the informed consent up to 30 days after the last dose (Up to Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs and TEAEs Leading Treatment Discontinuation
ParticipantsAripiprazole (Once Weekly)
Participants with Serious TEAEs5
Participants with Severe TEAEs8
Participants Discontinued Medication due to TEAE's6
Participants with TEAEs104
PrimaryNumber of Participants With Clinically Significant Changes in Laboratory Parameter Values

The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Participants with potentially clinically significant lab values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria were reported. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Laboratory Parameter Values
ParticipantsAripiprazole (Once Weekly)
Chemistry-Alkaline Phosphatase0
Chemistry-Alanine Aminotransferase1
Chemistry-Aspartate Aminotransferase1
Chemistry-Bilirubin, Total4
Chemistry-Calcium0
Chemistry-Chloride0
Chemistry-Creatine Phosphokinase4
Chemistry-Creatinine0
Chemistry-Glucose1
Chemistry-Glucose, Fasting1
Chemistry-HDL Cholesterol, Fasting3
Chemistry-Lactic Dehydrogenase1
Chemistry-LDL-Cholesterol, Fasting2
Chemistry-Potassium0
Chemistry-Sodium0
Chemistry- Triglycerides, Fasting19
Chemistry- Urea Nitrogen0
Chemistry-Uric Acid0
Urinalysis-Glucose, Urine3
Urinalysis-Protein, Urine1
Other-Prolactin3
Haematology-Eosinophils3
Haematology-Hematocrit0
Haematology-Hemoglobin3
Haematology-Neutrophils0
Haematology-Platelet Count0
Haematology-White Blood Count4
PrimaryNumber of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values

Incidence of clinically relevant abnormal ECG values were reported as change from Baseline in heart rate (Tachycardia - ≥15 beats per minute (bpm), Bradycardia ≤15 bpm; Rhythm (Sinus tachycardia ≥15 bpm increase, Sinus bradycardia decrease of ≥15 bpm from Baseline); Presence of - supraventricular premature beat; ventricular premature beat; supraventricular tachycardia; ventricular tachycardia; atrial fibrillation and flutter. Conduction - Presence of primary, secondary or tertiary atrioventricular block, left bundle-branch block, right bundle-branch block, pre-excitation syndrome, other intraventricular conduction blocked QRS ≥0.12 second increase of ≥0.02 second. Acute, subacute or old Infarction, Presence of myocardial ischemia, symmetrical T-wave inversion. Increase in QTc - QTc ≥450 msec ≥10% increase. Any clinically significant change from Baseline assessed by the Investigator are reported.

Time frame:
Baseline to Week 52
Reported as:
Number · participants
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values
participantsAripiprazole (Once Weekly)
Tachycardia1
Bradycardia0
Sinus Tachycardia1
Sinus Bradycardia0
Supraventricular Premature Beat4
Ventricular Premature Beat3
Supraventricular Tachycardia0
Ventricular Tachycardia0
Atrial Fibrillation0
Atrial Flutter0
Primary Atrioventricular Block0
Secondary Atrioventricular Block0
Tertiary Atrioventricular Block0
Left Bundle Branch Block0
Right Bundle Branch Block2
Pre-excitation Syndrome0
Other intraventricular conduction block0
Acute or Sub-acute Infarction0
Old Infarction0
Myocardial Ischemia0
Symmetrical T-Wave Inversion1
QT Interval cCorrected for Heart Rate by Bazett's Formula (QTB)3
QT Interval Corrected for Heart Rate by Fredericia's Formula (QTcF)0
QT Interval Corrected for Heart Rate by the US Food and Drug (QTcN)1
PrimaryNumber of Participants With Emergence of Suicidal Ideation, TEAEs Related to Suicide and Suicidality and Suicide Ideation From the Potential Suicide Events Recorded on the Columbia-Suicide Severity Rating Scale (C-SSRS)

Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Emergence of Suicidal Ideation, TEAEs Related to Suicide and Suicidality and Suicide Ideation From the Potential Suicide Events Recorded on the Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsAripiprazole (Once Weekly)
Emergence of Suicidal Ideation3
TEAEs related to Suicide3
Suicidality and Suicidal Ideation4
PrimaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score

The AIMS Scale is an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10) are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · score on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score
score on a scaleAripiprazole (Once Weekly)
Change at Week 4-0.1 ± 1.3
Change at Week 8-0.1 ± 1.6
Change at Week 12-0.4 ± 1.7
Change at Week 16-0.5 ± 2
Change at Week 20-0.5 ± 2
Change at Week 24-0.6 ± 2.5
Change at Week 32-0.8 ± 2.3
Change at Week 40-0.8 ± 2.4
Change at Week 52-0.9 ± 2.4
Change at Last Visit (Early Termination Visit Prior to or at Week 52-0.8 ± 2.3
PrimaryMean Change From Baseline in Body Mass Index (BMI)

The BMI kilogram/meter square (i.e. kg/m\^2) was calculated from the Baseline height and the weight at the current visit using one of the following formulae, as appropriate: Weight (kg) divided by \[Height (meters)\]\^2.

Time frame:
Baseline and Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · kg/m^2
Mean Change From Baseline in Body Mass Index (BMI)
kg/m^2Aripiprazole (Once Weekly)
Change at Week 120.6 ± 0.9
Change at Week 240.4 ± 1.5
Change at Week 520.7 ± 2
Change at Last Visit (Early Termination Visit Prior to or at Week 520.6 ± 1.8
PrimaryNumber of Participants With Clinically Significant Changes in Vital Signs

Vital signs assessments included orthostatic (supine and standing) blood pressure (BP) measured as millimeter of mercury \[mmHg\]), heart rate, (measured in beats per minute \[bpm\]), body weight (measured in kilograms \[kg\]) and body temperature. Incidence of clinically relevant abnormal values in heart rate, systolic and diastolic blood pressure and weight were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant has been supine for at least 5 minutes and again after the participant has been standing for approximately 2 minutes, but not more than 3 minutes.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsAripiprazole (Once Weekly)
Heart Rate Supine- Increase ≥15 bpm1
Heart Rate Supine- Decrease ≥15 bpm0
Heart Rate Standing-increase ≥15 bpm4
Heart Rate Standing- Decrease ≥15 bpm0
Systolic Supine BP- Increase ≥20 mmHg0
Systolic Supine BP- Decrease ≥20 mmHg1
Systolic Standing BP- Increase ≥20 mmHg0
Systolic Standing BP- Decrease ≥20 mmHg1
Diastolic Supine BP- Increase ≥15 mmHg0
Diastolic Supine BP- Decrease ≥15 mmHg0
Diastolic Standing BP- Increase ≥15 mmHg1
Diastolic Standing BP- Decrease ≥15 mmHg0
Orthostatic Hypotension2
Weight-Gain ≥ 7%82
Weight-Loss ≥ 7%6
PrimaryMean Change From Baseline in Simpson Angus Scale (SAS) Score

The SAS is a rating scale used to measure Extrapyramidal symptoms (EPS). The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · score on scale
Mean Change From Baseline in Simpson Angus Scale (SAS) Score
score on scaleAripiprazole (Once Weekly)
Change at Week 40 ± 0.3
Change at Week 80 ± 0.4
Change at Week 120 ± 0.3
Change at Week 160 ± 0.4
Change at Week 200 ± 0.2
Change at Week 240 ± 0.5
Change at Week 320 ± 0.4
Change at Week 400 ± 0.5
Change at Week 520 ± 0.5
Change at Last Visit (Week 52 or early termination Visit before Week 52)0 ± 0.4
PrimaryMean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score

The BARS was an EPS rating scale. The BARS was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia). A negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score
score on a scaleAripiprazole (Once Weekly)
Change at Week 40 ± 0.3
Change at Week 80 ± 0.2
Change at Week 120 ± 0.2
Change at Week 160 ± 0.2
Change at Week 200 ± 0.2
Change at Week 240 ± 0.1
Change at Week 320 ± 0.2
Change at Week 400 ± 0.2
Change at Week 520 ± 0.3
Change at Last Visit (Week 52 or early termination Visit before Week 52)0 ± 0.3
PrimaryMean Change From Baseline in Average Score of Attention-Deficit Disorder/Attention-Deficit Hyperactivity Disorder (ADD/ADHD) Sub-scale of the Swanson, Nolan and Pelham-IV (SNAP-IV)

The SNAP-IV, ADHD Inattention subscale contains 19 items, items 1 to 9 measure inattention, items 11 to 19 measure hyperactivity/impulsivity, and item 10 for inattention domain that scores the intensity of each item during the last seven days on a 0 to 3 scale (0=not at all, 1=just a little, 2=pretty much, 3=very much). The lowest possible score is 0; highest is 57. The negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Average Score of Attention-Deficit Disorder/Attention-Deficit Hyperactivity Disorder (ADD/ADHD) Sub-scale of the Swanson, Nolan and Pelham-IV (SNAP-IV)
score on a scaleAripiprazole (Once Weekly)
Change at Week 4-0.1 ± 0.3
Change at Week 80 ± 0.3
Change at Week 12-0.1 ± 0.3
Change at Week 16-0.1 ± 0.4
Change at Week 20-0.1 ± 0.3
Change at Week 24-0.2 ± 0.4
Change at Week 32-0.2 ± 0.4
Change at Week 40-0.2 ± 0.4
Change at Week 52-0.1 ± 0.4
Change at Last Visit (Week 52 or early termination Visit before Week 52)-0.1 ± 0.4
PrimaryMean Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Total Score

The CY-BOCS is used to assess characteristics of obsession and compulsion for the week prior to the interview. Nineteen items are rated in the CY-BOCS, but the total score is the sum of only items 1 to 10 (excluding items 1b and 6b). The obsession and compulsion subtotals are the sums of items 1 to 5 (excluding 1b) and 6 to 10 (excluding 6b), respectively. A missing value for any CY-BOCS item scale could result in a missing total score or obsession and compulsion subtotals of which the item scale is a component. At baseline, the full CY-BOCS interview is conducted. At all post-baseline time points, the "Questions on Obsessions" (items 1 to 5) and "Questions on Compulsions" (items 6 to 10) are reviewed and the target symptoms identified at baseline are the primary focus for rating severity. CY-BOCS total score could range from 0 to 40. Higher scores indicate worse outcome. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Total Score
score on a scaleAripiprazole (Once Weekly)
Change at Week 4-0.2 ± 1.6
Change at Week 8-0.2 ± 1.9
Change at Week 12-0.3 ± 1.8
Change at Week 16-0.4 ± 1.9
Change at Week 20-0.4 ± 2
Change at Week 24-0.5 ± 2.2
Change at Week 32-0.6 ± 2.5
Change at Week 40-0.6 ± 2.4
Change at Week 52-0.3 ± 2.4
Change at Last Visit (Week 52 or early termination Visit before Week 52)-0.3 ± 2.4
PrimaryMean Change From Baseline in Children's Depression Rating Scale Revised (CDRS-R) Total Score

The CDRS-R is composed of 17 interviewer-rated symptom areas: impaired schoolwork, difficulty having fun, social withdrawal, appetite disturbance, sleep disturbance, excessive fatigue, physical complaints, irritability, excessive guilt, low self-esteem, depressed feelings, morbid ideas, suicidal ideas, excessive weeping, depressed facial affect, listless speech, and hypoactivity. The CDRS-R total score is the sum of scores for the 17 symptom areas. A missing value for any CDRS-R item scale or a not rated item scale (indicated by the value of 0) could result in a missing total score. The CDRS-R total score is the sum of scores for the 17 symptom areas and could range from 17 to 113 with higher values indicating worse outcome. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Children's Depression Rating Scale Revised (CDRS-R) Total Score
score on a scaleAripiprazole (Once Weekly)
Change at Week 40 ± 2.3
Change at Week 80 ± 2.6
Change at Week 12-0.2 ± 3.1
Change at Week 16-0.4 ± 2.9
Change at Week 20-0.3 ± 3.1
Change at Week 24-0.2 ± 2.5
Change at Week 32-0.1 ± 2.8
Change at Week 40-0.4 ± 2.7
Change at Week 52-0.2 ± 3.3
Change at Last Visit (Week 52 or early termination Visit before Week 52)0.3 ± 4.1
PrimaryMean Change From Baseline in Pediatric Anxiety Rating Scale (PARS) Total Severity Score

The PARS has 2 sections: the symptom checklist and the severity items. The symptom checklist is used to determine the child's repertoire of symptoms during the past week. Information is elicited from the child and parent(s) and the rater then combines information from all informants using his/her best judgment. The 7-item severity list is used to determine severity of symptoms and the PARS total score. The time frame for the PARS rating is the past week. Only those symptoms endorsed for the past week are included in the symptom checklist and rated on the severity items. The PARS total severity score is the sum of items 2, 3, 5, 6, and 7. The total severity score ranges from 0 to 25, with 25 being the worst. Codes "8" (Not applicable) and "9" (Does not know) are not included in the summation (ie, equivalent to a score of 0 in the summation). A negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Pediatric Anxiety Rating Scale (PARS) Total Severity Score
score on a scaleAripiprazole (Once Weekly)
Change at Week 4-0.1 ± 2.6
Change at Week 8-0.2 ± 2.4
Change at Week 12-0.3 ± 1.8
Change at Week 16-0.3 ± 2
Change at Week 20-0.3 ± 2.1
Change at Week 24-0.3 ± 2.3
Change at Week 32-0.3 ± 2.4
Change at Week 40-0.6 ± 2.3
Change at Week 52-0.7 ± 2.4
Change at Last Visit (Week 52 or early termination Visit before Week 52)-0.3 ± 2.6
PrimaryMean Change From Baseline in Body Weight
Time frame:
Baseline to Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · kilogram
Mean Change From Baseline in Body Weight
kilogramAripiprazole (Once Weekly)
Change at Week 121.4 ± 2.3
Change at Week 242.5 ± 3.9
Change at Week 524.7 ± 6
Change at Last Visit (Week 52 or early termination Visit before Week 52)3.8 ± 5.1
PrimaryMean Change From Baseline in Waist Circumference

Waist circumference was recorded before a participant's meal and at approximately the same time at each visit. Measurement was accomplished by locating the upper hip bone and the top of the right iliac crest and placing the measuring tape in a horizontal plane around the abdomen at the level of the crest. Before reading the tape measure, the assessor assured that the tape was snug, but did not compress the skin, and is parallel to the floor. The measurement was made at the end of a normal exhalation.

Time frame:
Baseline to Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · centimeter
Mean Change From Baseline in Waist Circumference
centimeterAripiprazole (Once Weekly)
Change at Week 120.4 ± 3.9
Change at Week 241 ± 5.2
Change at Week 522.3 ± 6.8
Change at Last Visit (Week 52 or early termination Visit before Week 52)1.9 ± 5.8
SecondaryMean Change From Baseline in Yale Global Tic Severity Scale (YGTSS) Total Tic Score

The YGTSS is a semi-structured clinical interview designed to measure the tic severity. This scale consisted of a tic inventory, with 5 separate rating scales to rate the severity of symptoms, and an impairment ranking. Ratings were made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics, each including number, frequency, intensity, complexity, and interference. The YGTSS TTS was the summation of the severity scores of motor and vocal tics. The total tic score (TTS) ranged from 0 (none) to 50 (severe) with higher score represent more severe symptoms (A negative change from Baseline indicates improvement).

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · score on scale
Mean Change From Baseline in Yale Global Tic Severity Scale (YGTSS) Total Tic Score
score on scaleAripiprazole (Once Weekly)
Change at Week 4-2.6 ± 5.4
Change at Week 8-3.8 ± 5.6
Change at Week 12-4.5 ± 6.7
Change at Week 16-4.6 ± 6.8
Change at Week 20-5.5 ± 7.2
Change at Week 24-5.8 ± 7.9
Change at Week 32-6 ± 9.1
Change at Week 40-6.4 ± 9.3
Change at Week 52-5.8 ± 8.8
Change at Last Visit (Week 52 or early termination Visit before Week 52)-5.9 ± 8.4
SecondaryMean Change From Baseline in Clinical Global Impression for Tourette's Syndrome (CGI-TS) Severity of Illness Score

The severity of illness and efficacy of study medication for each participant were rated using the CGI-TS scale. The study physician rated the participants total improvement whether or not it is due to study treatment. All responses were compared to the participants condition at Baseline (Day 0). Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Clinical Global Impression for Tourette's Syndrome (CGI-TS) Severity of Illness Score
score on a scaleAripiprazole (Once Weekly)
Change at Week 4-0.2 ± 0.7
Change at Week 8-0.4 ± 0.8
Change at Week 12-0.4 ± 0.8
Change at Week 16-0.5 ± 0.8
Change at Week 20-0.6 ± 0.8
Change at Week 24-0.5 ± 0.9
Change at Week 32-0.6 ± 1
Change at Week 40-0.7 ± 1.1
Change at Week 52-0.7 ± 1.1
Change at Last Visit (Week 52 or early termination Visit before Week 52)-0.6 ± 1.1
SecondaryMean Change From Baseline in Total YGTSS Score

The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) of motor and vocal tics, and an impairment ranking. The Total YGTSS score is the summation of the severity scores of motor and vocal tics and also the ranking of impairment (range of 0 to 100). A missing value of a YGTSS item scale could result in a missing Total YGTSS score. A negative change in Total YGTSS score from baseline represents an improvement in symptoms.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Total YGTSS Score
score on a scaleAripiprazole (Once Weekly)
Change at Week 4-5.6 ± 10.4
Change at Week 8-7.4 ± 11.8
Change at Week 12-8.6 ± 12.9
Change at Week 16-9.4 ± 13.9
Change at Week 20-10.7 ± 14.9
Change at Week 24-10.4 ± 16
Change at Week 32-11.6 ± 17.5
Change at Week 40-12.6 ± 17.5
Change at Week 52-10.8 ± 17.4
Change at Last Visit (Week 52 or early termination Visit before Week 52)-11.4 ± 16.7
SecondaryResponse Rates

Response rates - clinical response was defined as percentage of participants \>25% improvement from Baseline to endpoint in YGTSS TTS OR a CGI-TS change score of 1 \[very much improved\] or 2 \[much improved\] at endpoint. The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) of motor and vocal tics, and an impairment ranking. The Total YGTSS score is the summation of the severity scores of motor and vocal tics and also the ranking of impairment (range of 0 to 100) with higher score representing severe symptoms.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Number · percentage of participants
Response Rates
percentage of participantsAripiprazole (Once Weekly)
Week 466.2
Week 869.7
Week 1272.6
Week 1672.3
Week 2074.2
Week 2471.8
Week 3277.8
Week 4080.8
Week 5276.5
Last Visit (Week 52 or early termination Visit before Week 52)71.3
SecondaryTreatment Discontinuation Rates

Treatment discontinuation rate was calculated as the percentage of participants who discontinued treatment.

Time frame:
Up to Week 53
Reported as:
Number · percentage of participants
Treatment Discontinuation Rates
percentage of participantsAripiprazole (Once Weekly)
All reasons47.6
Other than sponsor discontinued study site22.4
SecondaryMean Change From Baseline in Gilles de la Tourette Quality of Life (GTS-QOL) Overall Score

The GTS-QOL is a disease-specific patient-reported scale for the measurement of health-related quality of life in participants with Tourette's Disorder, taking into account the complexity of the clinical picture of the disease. The questionnaire consists of a 27-item Tourette's Disorder-specific scale with 4 subscales (psychological, physical, obsessional, and cognitive). The GTS-QOL total score ranged from 0 (extremely dissatisfied with life) and 100 (extremely satisfied with life). A positive change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 4, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Gilles de la Tourette Quality of Life (GTS-QOL) Overall Score
score on a scaleAripiprazole (Once Weekly)
Change at Week 4-2.9 ± 8.2
Change at Week 24-3.6 ± 11.3
Change at Week 52-4.3 ± 10.5
Change at Last Visit (Week 52 or early termination Visit before Week 52)-3.8 ± 10.9

Adverse events

Collected over From first dose up to 4 weeks post last dose (Up to 56 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole (Once Weekly)0/170 (0%)5/170 (2.9%)57/170 (33.5%)
Most frequent serious events
Most frequent serious events
EventAripiprazole (Once Weekly)
Blood creatinine phosphokinase increasedInvestigations1/170
Blood lactate dehydrogenase increasedInvestigations1/170
Alanine aminotransferase increasedInvestigations1/170
Aspartate aminotransferase increasedInvestigations1/170
Tourette's disorderCongenital, familial and genetic disorders1/170
TremorNervous system disorders1/170
Suicidal ideationPsychiatric disorders1/170
Type 1 diabetes mellitusMetabolism and nutrition disorders1/170
AppendicitisInfections and infestations1/170
Most frequent other events
Most frequent other events
EventAripiprazole (Once Weekly)
HeadacheNervous system disorders19/170
Weight increasedInvestigations14/170
VomitingGastrointestinal disorders12/170
NasopharyngitisInfections and infestations12/170
Upper respiratory tract infectionInfections and infestations12/170
SomnolenceNervous system disorders11/170
NauseaGastrointestinal disorders10/170

Baseline characteristics

The Enrolled Sample included participants who met the entrance criteria and assigned to the open label treatment (regardless of whether or not they were dosed with study drug).

Age, Continuous
Age, Continuous(years)Aripiprazole (Once Weekly)
Mean12.2 ± 2.9
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole (Once Weekly)
Female45
Male125
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aripiprazole (Once Weekly)
Hispanic or Latino31
Not Hispanic or Latino136
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aripiprazole (Once Weekly)
American Indian or Alaska Native1
Asian36
Native Hawaiian or Other Pacific Islander0
Black or African American13
White117
More than one race0
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(participants)Aripiprazole (Once Weekly)
Canada19
South Korea15
Romania8
Hungary14
United States50
Taiwan21
Ukraine21
Mexico14
Bulgaria5
Germany3
Weight
Weight(Kilogram)Aripiprazole (Once Weekly)
Mean51.5 ± 19
Height
Height(centimeter)Aripiprazole (Once Weekly)
Mean154.2 ± 16.4
Body Mass Index (BMI)
Body Mass Index (BMI)(Kilogram per meter square)Aripiprazole (Once Weekly)
Mean21.0 ± 4.7

1 further baseline measures are reported on the registry.

08

Study locations

80 sites
  • Dothan, Alabama 36303, United States
  • Little Rock, Arkansas 72205, United States
  • Los Angeles, California 90095, United States
  • Sacramento, California 95815, United States
  • San Diego, California 92108, United States
  • San Francisco, California 94143, United States
  • Santa Ana, California 92701, United States
  • Wildomar, California 92595, United States
  • Gainesville, Florida 32610, United States
  • Hialeah, Florida 33012, United States
  • Miami, Florida 33126, United States
  • Orange City, Florida 32763, United States
  • Saint Petersburg, Florida 33701, United States
  • Atlanta, Georgia 30308, United States
  • Atlanta, Georgia 30329, United States
  • Chicago, Illinois 60612, United States
  • Indianapolis, Indiana 46202-5200, United States
  • Overland Park, Kansas 66211, United States
  • New Orleans, Louisiana 70114, United States
  • Bloomfield Hills, Michigan 48302, United States
  • Omaha, Nebraska 68131, United States
  • Manhasset, New York 11030, United States
  • Staten Island, New York 10312, United States
  • Avon Lake, Ohio 44012, United States
  • Cincinnati, Ohio 45229-3039, United States
  • Cleveland, Ohio 44106, United States
  • Middleburg Heights, Ohio 44130, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Philadelphia, Pennsylvania 19139, United States
  • Dallas, Texas 75230, United States
  • San Antonio, Texas 78229, United States
  • San Antonio, Texas 78258, United States
  • Salt Lake City, Utah 84106, United States
  • Charlottesville, Virginia 22903, United States
  • Bothell, Washington 98011, United States
  • La Crosse, Wisconsin 54601, United States
  • Ruse, 7004, Bulgaria
  • Sofia, 1431, Bulgaria
  • Varna, 9010, Bulgaria
  • Calgary, T3B 6A8, Canada
  • Kelowna, V1Y 1Z9, Canada
  • Toronto, M5B 1T9, Canada
  • Toronto, M5T 2S8, Canada
  • Whitby, L1N 8M7, Canada
  • Aachen, 52074, Germany
  • Dresden, 1307, Germany
  • Hannover, 30625, Germany
  • Muenchen, 80336, Germany
  • Ulm, 89075, Germany
  • Budapest, 1021, Hungary
  • Szeged, 6725, Hungary
  • Gyeonggi-do, 420-767, Korea, Republic of
  • Gyeongsang, 626-770, Korea, Republic of
  • Incheon, 400-711, Korea, Republic of
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Seoul, 143-729, Korea, Republic of
  • Culiacán, 80020, Mexico
  • Delegación Miguel Hidalgo, 11000, Mexico
  • Durango, 34000, Mexico
  • Leon, 37000, Mexico
  • Monterrey, 64710, Mexico
  • Bucuresti, 41915, Romania
  • Cluj-Napoca, 400660, Romania
  • Craiova, 200620, Romania
  • Iasi, 700265, Romania
  • Changhua, 50006, Taiwan
  • Kaohsiung, 83301, Taiwan
  • Taichung, 40447, Taiwan
  • Taipei, 100, Taiwan
  • Taipei, 114, Taiwan
  • Donetsk, 83008, Ukraine
  • Kharkiv, 61068, Ukraine
  • Kharkiv, 61153, Ukraine
  • Kyiv, 03049, Ukraine
  • Kyiv, 4209, Ukraine
  • Lugansk, 91045, Ukraine
  • Poltava, 36006, Ukraine
  • Stepanivka, 73488, Ukraine
  • Vinnytsia, 21005, Ukraine
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/.

Data sharing details ↗ · clinical-trials.otsuka.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2011 to primary completion in Mar 2014, 28 months.

Results were first posted in Oct 2021, 7 years 6 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2011
First posted
Aug 15, 2011
StartActual
Oct 19, 2011
Primary completionActual
Mar 13, 2014
CompletionActual
Mar 13, 2014
Results delay requested
Mar 25, 2015
Results first posted
Oct 7, 2021
Last update
Oct 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01416441
Responsible party
Sponsor
First posted
Aug 15, 2011
Start date
Oct 19, 2011
Primary completion
Mar 13, 2014
Completion
Mar 13, 2014
Results posted
Oct 7, 2021
Last update
Oct 7, 2021

Study contacts

Eva Kohegyi, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion